Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CANFNASDAQ:CNSPNASDAQ:IMPLNASDAQ:INM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANFCan-Fite BioPharma$1.04-0.1%$1.27$0.98▼$4.69$3.68M1.18239,181 shs32,608 shsCNSPCNS Pharmaceuticals$1.10-3.9%$1.34$0.77▼$800.00$3.37M2.67679,378 shs193,322 shsIMPLImpel Pharmaceuticals$0.27$0.02▼$4.20$956K1.17682,655 shs720,000 shsINMInMed Pharmaceuticals$2.76+0.4%$2.66$1.72▼$15.70$3.33M0.21244,785 shs41,249 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANFCan-Fite BioPharma-0.10%-1.05%-11.95%-42.60%-56.34%CNSPCNS Pharmaceuticals-3.93%-14.06%+15.21%-66.57%-99.79%IMPLImpel Pharmaceuticals0.00%0.00%0.00%0.00%0.00%INMInMed Pharmaceuticals+0.36%-6.44%-6.44%-11.54%-60.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCANFCan-Fite BioPharma1.4431 of 5 stars3.70.00.00.00.00.01.3CNSPCNS Pharmaceuticals0.8352 of 5 stars3.32.00.00.00.00.00.0IMPLImpel PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AINMInMed PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCANFCan-Fite BioPharma 3.33Buy$14.001,247.45% UpsideCNSPCNS Pharmaceuticals 2.50Moderate Buy$25.002,172.73% UpsideIMPLImpel Pharmaceuticals 0.00N/AN/AN/AINMInMed Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IMPL, CNSP, CANF, and INM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025CNSPCNS PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/15/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/25/2025CNSPCNS PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/18/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/3/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCANFCan-Fite BioPharma$674K5.46N/AN/A$1.76 per share0.59CNSPCNS PharmaceuticalsN/AN/AN/AN/A($35.66) per shareN/AIMPLImpel Pharmaceuticals$20.99M0.00N/AN/A($1.86) per share0.00INMInMed Pharmaceuticals$4.92M0.68N/AN/A$5.12 per share0.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCANFCan-Fite BioPharma-$7.63M-$1.79N/AN/AN/AN/AN/AN/AN/ACNSPCNS Pharmaceuticals-$18.85M-$3,748.50N/A∞N/AN/AN/A-515.32%8/12/2025 (Estimated)IMPLImpel Pharmaceuticals-$106.31M-$3.13N/AN/AN/A-353.93%N/A-127.43%N/AINMInMed Pharmaceuticals-$7.68M-$12.09N/A∞N/A-163.75%-90.74%-71.70%N/ALatest IMPL, CNSP, CANF, and INM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CNSPCNS PharmaceuticalsN/A-$1.58N/A-$1.58N/AN/A5/12/2025Q3 2025INMInMed PharmaceuticalsN/A-$1.94N/A-$1.94N/A$1.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCANFCan-Fite BioPharmaN/AN/AN/AN/AN/ACNSPCNS PharmaceuticalsN/AN/AN/AN/AN/AIMPLImpel PharmaceuticalsN/AN/AN/AN/AN/AINMInMed PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCANFCan-Fite BioPharmaN/A2.93N/ACNSPCNS PharmaceuticalsN/A1.821.82IMPLImpel PharmaceuticalsN/A0.190.13INMInMed Pharmaceuticals0.093.052.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCANFCan-Fite BioPharma21.00%CNSPCNS Pharmaceuticals14.02%IMPLImpel Pharmaceuticals73.88%INMInMed Pharmaceuticals20.12%Insider OwnershipCompanyInsider OwnershipCANFCan-Fite BioPharma0.80%CNSPCNS Pharmaceuticals0.07%IMPLImpel Pharmaceuticals6.20%INMInMed Pharmaceuticals1.85%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCANFCan-Fite BioPharma83.54 millionN/ANot OptionableCNSPCNS Pharmaceuticals52.94 million57.45 millionNot OptionableIMPLImpel Pharmaceuticals16023.90 million22.42 millionNot OptionableINMInMed Pharmaceuticals101.21 million711,000Not OptionableIMPL, CNSP, CANF, and INM HeadlinesRecent News About These CompaniesInMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business UpdateMay 12, 2025 | newsfilecorp.comInMed Pharmaceuticals Board Reshuffle After Director ResignationFebruary 14, 2025 | tipranks.comInMed Pharmaceuticals Second Quarter 2025 Earnings: US$3.65 loss per share (vs US$3.71 loss in 2Q 2024)February 14, 2025 | finance.yahoo.comInMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business UpdateFebruary 12, 2025 | newsfilecorp.comInMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business UpdateFebruary 12, 2025 | newsfilecorp.comInMed Pharmaceuticals: InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular DegenerationFebruary 3, 2025 | finanznachrichten.deInMed advances AMD treatment with promising IVT drug formulationFebruary 3, 2025 | msn.comInMed Pharmaceuticals announces INM-089 IVT formulation as drug candidateFebruary 3, 2025 | markets.businessinsider.comInMed Advances INM-089 for Dry AMD Treatment with New Intravitreal FormulationFebruary 3, 2025 | tipranks.comInMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular DegenerationFebruary 3, 2025 | newsfilecorp.comInMed announces ‘positive’ results from in vivo preclinical Alzheimer’s studyJanuary 22, 2025 | markets.businessinsider.comInMed Pharmaceuticals secures international patentJanuary 22, 2025 | msn.comInMed Pharmaceuticals Announces Granting of Patent for Novel CompoundsJanuary 22, 2025 | newsfilecorp.comInMed Shares Rise, Study Indicates Alzheimer's Drug Could Lower NeuroinflammationJanuary 21, 2025 | marketwatch.comInMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease StudyJanuary 21, 2025 | newsfilecorp.comInMed Announces Results of 2024 Annual General MeetingDecember 18, 2024 | newsfilecorp.comInMed Enters Into Standby Equity Purchase AgreementDecember 17, 2024 | newsfilecorp.comInMed’s Study Highlights Cannabinol’s Potential in SkincareNovember 19, 2024 | markets.businessinsider.comInMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid SystemNovember 19, 2024 | newsfilecorp.comInMed Pharmaceuticals: InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business UpdateNovember 15, 2024 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long2 Reasons Netflix’s 40% Rally Is Far From OverBy Sam Quirke | May 20, 2025View 2 Reasons Netflix’s 40% Rally Is Far From OverNew Tariffs Hit Film Industry—What It Means for NetflixBy Gabriel Osorio-Mazilli | May 12, 2025View New Tariffs Hit Film Industry—What It Means for NetflixPegasystems: Mid-Cap GenAI Stock With Big Long-Term PotentialBy Leo Miller | April 30, 2025View Pegasystems: Mid-Cap GenAI Stock With Big Long-Term PotentialIMPL, CNSP, CANF, and INM Company DescriptionsCan-Fite BioPharma NYSE:CANF$1.04 0.00 (-0.10%) Closing price 05/23/2025 03:58 PM EasternExtended Trading$1.03 0.00 (-0.38%) As of 05/23/2025 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.CNS Pharmaceuticals NASDAQ:CNSP$1.10 -0.05 (-3.93%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.10 0.00 (-0.36%) As of 05/23/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Impel Pharmaceuticals NASDAQ:IMPLImpel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.InMed Pharmaceuticals NASDAQ:INM$2.76 +0.01 (+0.36%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$2.84 +0.08 (+2.90%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
